

Appendix 1. Search Strategies

Cancer – Imaging – Guidelines

Final Strategies

2024 May 25

MEDLINE

Database: Ovid MEDLINE(R) ALL <1946 to May 24, 2024>

Search Strategy:

--

```
1 exp Pancreatic Neoplasms/ (94600)
2 ((pancrea* or island cell? or islet cell? or "islet of
langerhans*") adj4 (mass or masses or neoplas* or
cancer* or tumor?r* or carcinogenes* or carcinoma* or
cystadenocarcinoma* or cystadeno-carcinoma* or
malignan* or oncolog* or adenocancer* or adeno-cancer*
or adenoma* or adenocarcinoma* or adeno-carcinoma*
or angiosarcoma* or angio-sarcoma* or blastoma* or
carcinosarcoma* or carcino-sarcoma* or
adenoacanthoma* or adeno-acanthoma* or epithelioma*
or hemangioendothelioma* or hemangio-endothelioma*
or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma*
or liposarcoma* or melanoma* or mesenchymoma* or
sarcoma* or thymoma* or granuloma* or
choriocarcinoma* or chorio-carcinoma* or cancerogenes*
or carcinoid*)).tw,kw,kf. (113232)
3 (Insuloma* or nesidioblastoma* or nesidio-blastoma*
or (pancrea* adj3 IPMN) or pancreatoblastoma* or
pancreato-blastoma* or solid pseudopapillary
tumor?r*).tw,kw,kf. (2227)
4 or/1-3 [PANCREATIC CANCER] (135560)
5 exp Liver Neoplasms/ (200287)
6 ((liver or livers or hepatic or hepatocellular* or hepato-
cellular* or hepatocyte*) adj4 (mass or masses or neoplas*
or cancer* or tumor?r* or carcinogenes* or carcinoma* or
cystadenocarcinoma* or cystadeno-carcinoma* or
malignan* or oncolog* or adenocancer* or adeno-cancer*
or adenoma* or adenocarcinoma* or adeno-carcinoma*
or angiosarcoma* or angio-sarcoma* or blastoma* or
carcinosarcoma* or carcino-sarcoma* or
adenoacanthoma* or adeno-acanthoma* or epithelioma*
or hemangioendothelioma* or hemangio-endothelioma*
or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma*
or liposarcoma* or melanoma* or mesenchymoma* or
sarcoma* or thymoma* or granuloma* or
choriocarcinoma* or chorio-carcinoma* or cancerogenes*
or carcinoid*)).tw,kw,kf. (223931)
7 hepatoma?.tw,kw,kf. (30793)
8 or/5-7 [LIVER CANCER] (302049)
9 exp Colorectal Neoplasms/ (246062)
10 ((anal or anus or anorectal* or ano-rectal* or
circumanal* or circum-anal* or perianal* or peri-anal* or
perirectal* or peri-rectal* or bowel? or colon or colons or
colonic or colorect* or rectal or rectocolonic* or recto-
colonic* or rectum or sigmoid*) adj4 (mass or masses or
neoplas* or cancer* or tumor?r* or carcinogenes* or
```

```
carcinoma* or cystadenocarcinoma* or cystadeno-
carcinoma* or malignan* or oncolog* or adenocancer* or
adeno-cancer* or adenoma* or adenocarcinoma* or
adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or
blastoma* or carcinosarcoma* or carcino-sarcoma* or
adenoacanthoma* or adeno-acanthoma* or epithelioma*
or hemangioendothelioma* or hemangio-endothelioma*
or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma*
or liposarcoma* or melanoma* or mesenchymoma* or
sarcoma* or thymoma* or granuloma* or
choriocarcinoma* or chorio-carcinoma* or cancerogenes*
or carcinoid*)).tw,kw,kf. (312406)
11 (Lynch adj2 (cancer? or syndrome?)).tw,kw,kf. (4633)
12 or/9-11 [BOWEL/COLORECTAL CANCER] (359323)
13 Penile Neoplasms/ (6044)
14 ((penile or penis or penises) adj4 (mass or masses or
neoplas* or cancer* or tumor?r* or carcinogenes* or
carcinoma* or cystadenocarcinoma* or cystadeno-
carcinoma* or malignan* or oncolog* or adenocancer* or
adeno-cancer* or adenoma* or adenocarcinoma* or
adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or
blastoma* or carcinosarcoma* or carcino-sarcoma* or
adenoacanthoma* or adeno-acanthoma* or epithelioma*
or hemangioendothelioma* or hemangio-endothelioma*
or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma*
or liposarcoma* or melanoma* or mesenchymoma* or
sarcoma* or thymoma* or granuloma* or
choriocarcinoma* or chorio-carcinoma* or cancerogenes*
or carcinoid*)).tw,kw,kf. (6247)
15 or/13-14 [PENILE CANCER] (8137)
16 exp Ovarian Neoplasms/ (98171)
17 ((ovary or ovaries or ovarian or theca cell?) adj4
(mass or masses or neoplas* or cancer* or tumor?r* or
carcinogenes* or carcinoma* or cystadenocarcinoma* or
cystadeno-carcinoma* or malignan* or oncolog* or
adenocancer* or adeno-cancer* or adenoma* or
adenocarcinoma* or adeno-carcinoma* or angiosarcoma*
or angio-sarcoma* or blastoma* or carcinosarcoma* or
carcino-sarcoma* or adenoacanthoma* or adeno-
acanthoma* or epithelioma* or hemangioendothelioma*
or hemangio-endothelioma* or leiomyosarcoma* or
leiomyo-sarcoma* or liposarcoma* or liposarcoma* or
melanoma* or mesenchymoma* or sarcoma* or
thymoma* or granuloma* or choriocarcinoma* or chorio-
carcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf.
(118282)
18 (androblastoma* or andro-blastoma* or
arrhenoblastoma* or arrheno-blastoma* or luteinoma* or
luteoma* or thecoma*).tw,kw,kf. (1167)
19 ((Brenner* or granulosa cell? or sertoli-leydig cell?)
adj4 (mass or masses or neoplas* or cancer* or tumor?r*
or carcinogenes* or carcinoma* or cystadenocarcinoma*
or cystadeno-carcinoma* or malignan* or oncolog* or
adenocancer* or adeno-cancer* or adenoma* or
adenocarcinoma* or adeno-carcinoma* or angiosarcoma*
or angio-sarcoma* or blastoma* or carcinosarcoma* or
```

Appendix 1. Search Strategies

carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or choriocarcinoma* or cancerogenes* or carcinoid*))).tw,kw,kf. (4094)

20 or/16-19 [OVARIAN CANCER] (139979)

21 Uterine Cervical Neoplasms/ (87692)

22 ((cervical or cervix) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*))).tw,kw,kf. (112150)

23 or/21-22 [CERVICAL CANCER] (131221)

24 exp Endometrial Neoplasms/ (26961)

25 (endometr* adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*))).tw,kw,kf. (47039)

26 or/24-25 [ENDOMETRIAL CANCER] (50590)

27 Vulvar Neoplasms/ (8989)

28 ((vulva or vulvar) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*))).tw,kw,kf. (8005)

29 or/27-28 [VULVAR CANCER] (11522)

30 Vaginal Neoplasms/ (5523)

31 ((vagina* or vulvovagina* or vulvo-vagina*) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or choriocarcinoma* or cancerogenes* or carcinoid*))).tw,kw,kf. (7728)

32 or/30-31 [VAGINAL CANCER] (10167)

33 exp Uterine Neoplasms/ (151551)

34 ((uterine or uterus or uteri or womb?) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or choriocarcinoma* or cancerogenes* or carcinoid*))).tw,kw,kf. (40720)

35 or/33-34 [UTERINE CANCER] (163210)

36 Hematologic Neoplasms/ (17580)

37 ((blood or h?ematolog* or h?ematopoietic*) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or choriocarcinoma* or cancerogenes* or carcinoid*))).tw,kw,kf. (116066)

38 ((polycyth?em* or poly-cyth?em*) adj2 vera).tw,kw,kf. (7669)

39 exp Leukemia/ (258493)

40 (leuk?emi* or leucocyth?emi*).tw,kw,kf. (311070)

41 exp Lymphoma/ (190766)

42 (lymphoma* or germinoblastoma* or germinoblastic sarcoma* or germinoblastic sarcoma* or hodgkin* or "hodgkin's" or lymphatic sarcoma* or lymphogranuloma* or lympho-granuloma* or

Appendix 1. Search Strategies

lymphosarcoma* or lympho-sarcoma* or nonhodgkin* or non-hodgkin* or reticulolymphosarcoma* or reticulo-lymphosarcoma* or reticulo-lympho-sarcoma* or reticulolympho-sarcoma* or reticulosarcoma* or reticulo-sarcoma*).tw,kw,kf. (241948)

43 or/36-42 [HEMATOLOGICAL CANCER] (690612)

44 exp Skin Neoplasms/ (203956)

45 (acanthoma* or mastocytoma* or melanoma*).tw,kw,kf. (148028)

46 ((basal cell? or derm* or epiderm* or sebaceous gland or skin or squamous) adj4 (mass or masses or neoplas* or cancer* or tumor* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadenocarcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*).tw,kw,kf. (240327)

47 or/44-46 [SKIN CANCER] (435673)

48 4 or 8 or 12 or 15 or 20 or 23 or 26 or 29 or 32 or 35 or 43 or 47 [ALL CANCERS OF INTEREST] (2076303)

49 Diagnostic Imaging/ (46991)

50 dg.fs. [diagnostic imaging] (1497809)

51 (diagnos* adj3 (image? or imaging)).tw,kw,kf. (62266)

52 (x-ray* or xray*).tw,kw,kf. (455039)

53 Image Interpretation, Computer-Assisted/ (48077)

54 exp Imaging, Three-Dimensional/ (93058)

55 ((3D or 3-D or 3-dimension* or three dimension*) adj (image? or imaging)).tw,kw,kf. (22919)

56 exp Ultrasonography/ (496255)

57 (ultrasound* or ultrasonograph* or ultra-sonograph* or ultrasonic* or ultra-sonic*).tw,kw,kf. (483666)

58 (echograph* or echo-graph* or echotomograph* or echo-tomograph* or echosonograph* or echo sonograph*).tw,kw,kf. (11356)

59 exp Radiography/ (1219475)

60 (radiograph* or radiographic imag* or roentgenograph* or roentgeno-graph*).tw,kw,kf. (292900)

61 (fluoroscop* or fluoro-scop*).tw,kw,kf. (35613)

62 exp Radionuclide Imaging/ (240830)

63 ((radionuclide* adj2 imag*) or (radio-nuclide* adj2 imag*) or (radionuclide* adj2 scan*) or (radio-nuclide* adj2 scan*) or (radioisotope* adj2 imag*) or (radio-isotope* adj2 imag*) or (radioisotope* adj2 scan*) or (radio-isotope* adj2 scan*) or scintigra* or scinti-gra* or scintiphotograph* or scinti-photograph* or scintiscan* or scinti-scan* or scanograph* or lymphoscintigra* or lympho-scintigra*).tw,kw,kf. (64913)

64 exp Tomography/ (1104870)

65 (tomograph* or tomo-graph*).tw,kw,kf. (557288)

66 (CAT scan* or CT scan* or PET scan* or PET imag* or PT scan* or PT imag*).tw,kw,kf. (153885)

67 (SPECTCT or SPECT CT or "SPECT/CT").tw,kw,kf. (6027)

68 (magnetic resonance imag* or MRI or MRIs or fMRI or fMRIs or NMR imag* or chemical shift imag* or magneti#ation transfer contrast imag* or spin echo imag* or zeugmatograph* or zeugmato-graph*).tw,kw,kf. (544120)

69 (cineradiograph* or cine-radiograph* or cinefluorograph* or cine-fluorograph* or radiocinematograph* or radio-cinematograph*).tw,kw,kf. (1833)

70 Nuclear Medicine/ (6898)

71 ((nuclear or atomic) adj1 medicine?).tw,kw,kf. (16827)

72 (nuclear adj1 radiolog*).tw,kw,kf. (589)

73 (sialogra* or salivogra* or sialoscintigra* or sialoscintigra*).tw,kw,kf. (1408)

74 (enteroclys* or enterogra*).tw,kw,kf. (2362)

75 (esophagra* or oesophagra* or esophagogra* or oesophagogra*).tw,kw,kf. (2679)

76 ((CT or virtual) adj colonoscop*).tw,kw,kf. (739)

77 (contrast adj (study or studies or medium)).tw,kw,kf. (18544)

78 (cholangiopancreatogra* or cholangio-pancreatogra* or ERCP or MRCP).tw,kw,kf. (20992)

79 cholecystogra*.tw,kw,kf. (2646)

80 (angiograph* or angio-graph* or angiogram* or angio-gram*).tw,kw,kf. (241414)

81 (perfusion adj3 (image? or imaging)).tw,kw,kf. (17225)

82 or/49-81 [IMAGING] (3568535)

83 48 and 82 [ALL CANCERS OF INTEREST - IMAGING] (248962)

84 exp Animals/ not Humans/ (5224753)

85 83 not 84 [ANIMAL-ONLY RECORDS REMOVED] (240908)

86 (case reports or address or autobiography or bibliography or biography or comment or dictionary or directory or editorial or "expression of concern" or festschrift or historical article or interactive tutorial or lecture or legal case or legislation or news or newspaper article or patient education handout or personal narrative or portrait or video-audio media or webcast or (letter not (letter and randomized controlled trial))).pt. (5075596)

87 85 not 86 [IRRELEVANT PUBLICATION TYPES REMOVED] (152705)

88 exp Guidelines as Topic/ (173680)

89 exp Clinical Protocols/ (193975)

90 Guideline.pt. (16382)

91 Practice Guideline.pt. (31451)

92 standards.fs. (769691)

93 Consensus Development Conference.pt. (12410)

94 Consensus Development Conference, NIH.pt. (801)

95 (consensus or guideline* or guidance? or standards or recommendation*).ti,kw,kf. (250775)

96 (expert consensus or consensus statement* or consensus conference* or clinical guideline? or practice guideline? or treatment guideline? or practice parameter*

Appendix 1. Search Strategies

or position statement* or policy statement* or CPG or CPGs).tw,kw,kf. (137395)
97 or/88-96 [GUIDELINE FILTER] (1315498)
98 87 and 97 [ALL CANCERS OF INTEREST - IMAGING - GUIDELINES] (9101)
99 limit 98 to yr="2019-current" [DATE LIMIT APPLIED] (2320)

Embase

Database: Embase <1974 to 2024 May 24>

Search Strategy:

--

1 exp pancreas tumor/ (200167)
2 ((pancrea* or island cell? or islet cell? or "islet of langerhans*") adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (177103)
3 (Insuloma* or nesidioblastoma* or nesidio-blastoma* or (pancrea* adj3 IPMN) or pancreatoblastoma* or pancreato-blastoma* or solid pseudopapillary tumor?r*).tw,kw,kf. (3797)
4 or/1-3 [PANCREATIC CANCER] (237944)
5 exp liver tumor/ (370739)
6 ((liver or livers or hepatic or hepatocellular* or hepatocellular* or hepatocyte*) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (316046)
7 hepatoma?.tw,kw,kf. (35095)
8 or/5-7 [LIVER CANCER] (463254)
9 exp intestine tumor/ (536186)
10 ((anal or anus or anorectal* or ano-rectal* or circumanal* or circum-anal* or perianal* or peri-anal* or perirectal* or peri-rectal* or bowel? or colon or colons or

colonic or colorect* or rectal or rectocolonic* or rectocolonic* or rectum or sigmoid*) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (453379)
11 (Lynch adj2 (cancer? or syndrome?)).tw,kw,kf. (8455)
12 or/9-11 [BOWEL/COLORECTAL CANCER] (615335)
13 exp penis tumor/ (11674)
14 ((penile or penis or penises) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (8515)
15 or/13-14 [PENILE CANCER] (13803)
16 exp ovary tumor/ (190047)
17 ((ovary or ovaries or ovarian or theca cell?) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (167789)
18 (androblastoma* or andro-blastoma* or arrhenoblastoma* or arrheno-blastoma* or luteinoma* or luteoma* or thecoma*).tw,kw,kf. (956)
19 ((Brenner* or granulosa cell? or sertoli-leydig cell?) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma*

Appendix 1. Search Strategies

or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or choriocarcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (4887)

20 or/16-19 [OVARIAN CANCER] (222851)

21 exp uterine cervix tumor/ (143185)

22 ((cervical or cervix) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (142396)

23 or/21-22 [CERVICAL CANCER] (178591)

24 exp endometrium tumor/ (87440)

25 (endometr* adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (70818)

26 or/24-25 [ENDOMETRIAL CANCER] (102757)

27 exp vulva tumor/ (14726)

28 ((vulva or vulvar) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or chorio-carcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (11001)

29 or/27-28 [VULVAR CANCER] (18042)

30 exp vagina tumor/ (15011)

31 ((vagina* or vulvovagina* or vulvo-vagina*) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or choriocarcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (9764)

32 or/30-31 [VAGINAL CANCER] (20480)

33 exp uterus tumor/ (256282)

34 ((uterine or uterus or uteri or womb?) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or choriocarcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (44077)

35 or/33-34 [UTERINE CANCER] (265459)

36 exp hematopoietic system tumor/ (785585)

37 exp hematologic malignancy/ (772732)

38 ((blood or h?ematolog* or h?ematopoietic*) adj4 (mass or masses or neoplas* or cancer* or tumor?r* or carcinogenes* or carcinoma* or cystadenocarcinoma* or cystadeno-carcinoma* or malignan* or oncolog* or adenocancer* or adeno-cancer* or adenoma* or adenocarcinoma* or adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or blastoma* or carcinosarcoma* or carcino-sarcoma* or adenoacanthoma* or adeno-acanthoma* or epithelioma* or hemangioendothelioma* or hemangio-endothelioma* or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma* or liposarcoma* or melanoma* or mesenchymoma* or sarcoma* or thymoma* or granuloma* or choriocarcinoma* or choriocarcinoma* or cancerogenes* or carcinoid*)).tw,kw,kf. (192357)

39 ((polycyth?em* or poly-cyth?em*) adj2 vera).tw,kw,kf. (10808)

40 exp leukemia/ (382831)

41 (leuk?emi* or leucocyth?emi*).tw,kw,kf. (428648)

42 exp lymphoma/ (340500)

43 (lymphoma* or germinoblastoma* or germino-blastoma* or germinoblastic sarcoma* or germino-blastic

Appendix 1. Search Strategies

sarcoma* or hodgkin? or "hodgkin's" or lymphatic
sarcoma* or lymphogranuloma* or lympho-granuloma* or
lymphosarcoma* or lympho-sarcoma* or nonhodgkin* or
non-hodgkin* or reticulolymphosarcoma* or reticulo-
lymphosarcoma* or reticulo-lympho-sarcoma* or
reticulolympho-sarcoma* or reticulosarcoma* or reticulo-
sarcoma*).tw,kw,kf. (342668)
44 or/36-43 [HEMATOLOGICAL CANCER] (1089988)
45 exp skin tumor/ (250242)
46 (acanthoma* or mastocytoma* or
melanoma*).tw,kw,kf. (207631)
47 ((basal cell? or derm* or epiderm* or sebaceous
gland or skin or squamous) adj4 (mass or masses or
neoplas* or cancer* or tumor* or carcinogenes* or
carcinoma* or cystadenocarcinoma* or cystadeno-
carcinoma* or malignan* or oncolog* or adenocancer* or
adeno-cancer* or adenoma* or adenocarcinoma* or
adeno-carcinoma* or angiosarcoma* or angio-sarcoma* or
blastoma* or carcinosarcoma* or carcino-sarcoma* or
adenoacanthoma* or adeno-acanthoma* or epithelioma*
or hemangioendothelioma* or hemangio-endothelioma*
or leiomyosarcoma* or leiomyo-sarcoma* or liposarcoma*
or liposarcoma* or melanoma* or mesenchymoma* or
sarcoma* or thymoma* or granuloma* or
choriocarcinoma* or chorio-carcinoma* or cancerogenes*
or carcinoid*).tw,kw,kf. (324078)
48 or/45-47 [SKIN CANCER] (635387)
49 4 or 8 or 12 or 15 or 20 or 23 or 26 or 29 or 32 or 35
or 44 or 48 [ALL CANCERS OF INTEREST] (3087163)
50 diagnostic imaging/ (258325)
51 (diagnos* adj3 (image? or imaging)).tw,kw,kf. (89335)
52 (x-ray* or xray*).tw,kw,kf. (517000)
53 computer assisted tomography/ (947857)
54 computer assisted diagnosis/ (42959)
55 exp three-dimensional imaging/ (134226)
56 ((3D or 3-D or 3-dimension* or three dimension*) adj
(image? or imaging)).tw,kw,kf. (30108)
57 exp echography/ (1053279)
58 (ultrasound* or ultrasonograph* or ultra-sonograph*
or ultrasonic* or ultra-sonic*).tw,kw,kf. (718104)
59 (echograph* or echo-graph* or echotomograph* or
echo-tomograph* or echosonograph* or echo
sonograph*).tw,kw,kf. (15093)
60 exp radiography/ (1370605)
61 (radiograph* or radiographic imag* or
roentgenograph* or roentgeno-graph*).tw,kw,kf. (340343)
62 (fluoroscop* or fluoro-scop*).tw,kw,kf. (58560)
63 exp scintiscanning/ (199057)
64 ((radionuclide* adj2 imag*) or (radio-nuclide* adj2
imag*) or (radionuclide* adj2 scan*) or (radio-nuclide*
adj2 scan*) or radioisotope* adj2 imag*) or (radio-
isotope* adj2 imag*) or (radioisotope* adj2 scan*) or
(radio-isotope* adj2 scan*) or scintigra* or scinti-gra* or
scintiphotograph* or scinti-photograph* or scintiscan* or
scinti-scan* or scanograph* or lymphoscintigra* or
lympho-scintigra*).tw,kw,kf. (89614)
65 exp tomography/ (2526390)
66 (tomograph* or tomo-graph*).tw,kw,kf. (722588)

67 (CAT scan* or CT scan* or PET scan* or PET imag* or
PT scan* or PT imag*).tw,kw,kf. (282695)
68 (SPECTCT or SPECT CT or "SPECT/CT").tw,kw,kf.
(14038)
69 (magnetic resonance imag* or MRI or MRIs or fMRI
or fMRIs or NMR imag* or chemical shift imag* or
magnetization transfer contrast imag* or spin echo imag*
or zeugmatograph* or zeugmato-graph*).tw,kw,kf.
(850618)
70 (cineradiograph* or cine-radiograph* or
cinefluorograph* or cine-fluorograph* or
radiocinematograph* or radio-cinematograph*).tw,kw,kf.
(954)
71 nuclear medicine/ (37885)
72 ((nuclear or atomic) adj1 medicine?).tw,kw,kf.
(33692)
73 (nuclear adj1 radiolog*).tw,kw,kf. (868)
74 (sialogra* or salivogra* or sialoscintigra* or sialo-
scintigra*).tw,kw,kf. (1418)
75 (enteroclys* or enterogra*).tw,kw,kf. (4463)
76 (esophagra* or oesophagra* or esophagogra* or
oesophagogra*).tw,kw,kf. (4799)
77 ((CT or virtual) adj colonoscop*).tw,kw,kf. (1238)
78 (contrast adj (study or studies or medium)).tw,kw,kf.
(23489)
79 (cholangiopancreatogra* or cholangio-pancreatogra*
or ERCP or MRCP).tw,kw,kf. (40695)
80 cholecystogra*.tw,kw,kf. (1274)
81 (angiograph* or angio-graph* or angiogram* or
angio-gram*).tw,kw,kf. (349214)
82 (perfusion adj3 (image? or imaging)).tw,kw,kf.
(28317)
83 or/50-82 [IMAGING] (5154190)
84 49 and 83 [CANCERS OF INTEREST - IMAGING]
(508063)
85 (exp animal/ or exp animal model/ or exp animal
experiment/ or nonhuman/ or exp vertebrate/) not (exp
human/ or exp human experiment/) (7447059)
86 84 not 85 [ANIMAL-ONLY REMOVED] (491414)
87 (conference abstract or editorial or letter).pt.
(7295874)
88 case report/ or exp case study/ or directory/
(3086481)
89 86 not (87 or 88) [IRRELEVANT PUBLICATION TYPES
REMOVED] (211133)
90 exp practice guideline/ (749127)
91 (consensus or guideline* or guidance? or standards
or recommendation*).ti,kw,kf. (330766)
92 (expert consensus or consensus statement* or
consensus conference* or clinical guideline? or practice
guideline? or treatment guideline? or practice parameter*
or position statement* or policy statement* or CPG or
CPGs).tw,kw,kf. (197511)
93 or/90-92 [GUIDELINE FILTER] (1040002)
94 89 and 93 [GUIDELINES] (10433)
95 limit 94 to yr="2019-current" [DATE LIMIT APPLIED]
(3897)

Appendix 2. Potentially relevant non-English guidelines

1. Wang ZY, Xia DD, Han GH. [Excerpt from the 2023 American Association for the Study of Liver Diseases practice guideline: prevention, diagnosis, and treatment of hepatocellular carcinoma]. *Zhonghua ganzangbing zazhi = Chinese journal of hepatology* 2023; 31:1262-1265.
2. Collineau, Berenice, Genestie, Catherine, Croce, Sabrina, Meeus, Pierre, Floquet, Anne, Guyon, Frederic, Llacer-Moscardo, Carmen, Lebreton, Coriolan, Taieb, Sophie, Toulmonde, Maud, Blay, Jean Yves, Bonvalot, Sylvie, Ray-Coquard, Isabelle, Pautier, Patricia, Duffaud, Florence. [Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups]. *Leiomyosarcomes uterins - Referentiel de prise en charge du GSF-GETO/NETSARC+ et du groupe TMRG.* 2023. 110:440-449
3. Grenacher, L., Juchems, M., Schreyer, A. G., Wessling, J., Ringe, K. I., Uhl, W., Mayerle, J., Seufferlein, T.. [Diagnostic Imaging of pancreatic carcinoma-Update of the new guideline]. *Diagnostik beim Pankreaskarzinom - Update in der neuen Leitlinie..* 2022. 93:429-440
4. Wang, Y., Yang, S.. [Imaging modalities in the assessment of presacral recurrent rectal cancer]. *Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.* 2020. 23:456-460
5. Anonymous. [Chinese expert consensus on the diagnosis and treatment of presacral recurrent rectal cancer]. *Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.* 2020. 23:438-444
6. Anonymous. [Chinese expert consensus on multidisciplinary management of malignant tumor-associated acute abdomen]. *Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.* 2020. 23:421-437
7. Zilliox, M., Lallemand, M., Thomassin-Naggara, I., Ramanah, R.. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Pregnancy]. *Tumeurs frontieres de l'ovaire.* Recommandations pour la pratique clinique du CNGOF - Grossesse. 2020. 48:322-329
8. Thomassin-Naggara I, Darai E, Lecuru F, Fournier L. [Diagnostic value of imaging (ultrasonography, doppler, CT, MR, PET-CT) for the diagnosis of a suspicious ovarian mass and staging of ovarian, tubal or primary peritoneal cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa] 2019; 47:123-133.
9. Rubtsova, N. A., Berezovskaia, T. P., Bychenko, V. G., Pavlovskaya, E. A., Solopova, A. E., Agababyan, T. A., Khodzhibekova, M. M., Ryzhkova, D. V., Chekalova, M. A., Meshkova, I. E., Gazhonova, V. E., Gus, A. I., Bagnenko, S. S., Medvedeva, B. M., Ashrafyan, L. A., Novikova, E. G., Berlev, I. V., Demidova, L. V., Krikunova, L. I., Kolomiets, L. A.. *Imaging of cervical cancer. Consensus of experts. Medical Visualization.* 2024. 28:141-156
10. Solodkiy, V. A., Nudnov, N. V., Aksenova, S. P., Rubtsova, N. A., Sinitsyn, V. E., Berezovskaia, T. P., Ivashina, S. V., Bychenko, V. G., Mishchenko, A. V., Khodzhibekova, M. M., Chekalova, M. A., Antonova, I. B., Ashrafyan, L. A., Novikova, E. G., Krikunova, L. I.. *Imaging of vaginal cancer. Consensus of experts. Medical Visualization.* 2023. 27:124-137
11. Zhaoshen, L., Zhendong, J., Xun, L.. *Chinese guideline for diagnosis of pancreatic cystic neoplasm (2022). Chinese Journal of Digestive Endoscopy.* 2022. 39:949-960
12. He, W., Chen, S.. *Chinese experts consensus on contrast-enhanced ultrasound in endometrial cancer. Chinese Journal of Medical Imaging Technology.* 2023. 39:641-645
13. Takemura, N., Tateishi, R., Yamashita, T., Watadani, T., Kaibori, M., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Aikata, H., Iijima, H., Ueshima, K., Ohkawa, K., Genda, T., Tsuchiya, K., Torimura, T., Ikeda, M., Furuse, J., Akahane, M.,

- Kobayashi, S., Sakurai, H., Takeda, A., Murakami, T., Motosugi, U., Matsuyama, Y., Kudo, M., Hasegawa, K.. Revisions of the clinical practice guidelines for hepatocellular carcinoma in 2021 version. *Kanzo/Acta Hepatologica Japonica*. 2023. 64:109-121
14. Li, Z., Jin, Z., Li, X.. Chinese guidelines for the diagnosis and treatment of pancreatic cystic neoplasm(2022). *Journal of Clinical Hepatology*. 2023. 39:290-298
15. Wu W, Chen J, Bai C, Yihebal C, Du Y, Feng S, Huo L, Jiang Y, Li J, Lou W, Luo J, Shao C, Shen L, Wang F, Wang L, Wang O, Wang Y, Wu H, Xing X, Xu J, Xue H, Xue L, Yang Y, Yu X, Yuan C, Zhao H, Zhu X, Zhao Y. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). *Medical Journal of Peking Union Medical College Hospital*. 2021; 12:460-480.
16. Steiner, E., Horn, L. C., Mokry, T., Lax, S. F., Mayr, D., Cremer, W., Prompeler, H. J., Grab, D., Reinhardt, M.. Screening, diagnosis, imaging, and pathology. *Gynakologie*. 2022. 55:481-492
17. Solopova, A. E., Ukraintsev, N. I., Rubtsova, N. A.. MAGNETIC RESONANCE IMAGING IN THE INITIAL STAGING OF CERVICAL CANCER: UPDATING THE 2021 ESUR GUIDELINES. *Akusherstvo i Ginekologiya (Russian Federation)*. 2022. 2022:36-46
18. Genes, W. P., Fierro, M. C., Guerrero, A. E., Lozano, A. M. M., Roza, Y. C. T., Sanchez, A. F. P. Colombian Society of Urology Penile Cancer Guideline. *Urologia Colombiana*. 2022. 31:32-40
19. Voesch, S., Bitzer, M., Malek, N.. Guiding questions for the new clinical practice guidelines: Management of hepatocellular carcinoma. *Verdauungskrankheiten*. 2021. 39:158-163
20. Reig, M., Forner, A., Avila, M. A., Ayuso, C., Minguez, B., Varela, M., Bilbao, I., Bilbao, J. I., Burrel, M., Bustamante, J., Ferrer, J., Gomez, M. A., Llovet, J. M., De la Mata, M., Matilla, A., Pardo, F., Pastrana, M. A., Rodriguez-Peralvarez, M., Tabernero, J., Urbano, J., Vera, R., Sangro, B., Bruix, J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. *Medicina Clinica*. 2021. 156:463.e1-463.e30

Appendix 3. AGREE-II assessments

Guideline	Domain 1				Domain 2				Domain 3									Domain 4				Domain 5					Domain 6			Overall quality
	1	2	3	Score (%)	4	5	6	Score (%)	7	8	9	10	11	12	13	14	Score (%)	15	16	17	Score (%)	18	19	20	21	Score (%)	22	23	Score (%)	
AIOM 2020 [1]	3	3	3	9 (100)	3	3	3	9 (100)	3	3	3	3	1	3	3	1	20 (83)	3	1	3	7 (78)	1	1	1	1	4 (33)	3	3	6 (100)	Moderate
JPS 2020 [2]	3	3	3	9 (100)	3	3	3	9 (100)	3	1	3	3	3	1	3	1	18 (75)	3	3	3	9 (100)	1	3	3	1	8 (67)	3	3	6 (100)	High
Korean NNC 2021 [3]	3	3	3	9 (100)	3	1	3	7 (78)	3	3	3	3	3	3	3	1	22 (92)	3	3	3	9 (100)	3	3	3	1	10 (83)	3	3	6 (100)	High
AASLD 2023 [4]	3	2	3	8 (89)	3	1	2	6 (67)	3	1	3	1	3	3	3	1	18 (75)	3	3	3	9 (100)	1	3	3	3	10 (83)	3	3	6 (100)	High
ACR 2020 [5]	3	3	3	9 (100)	3	1	3	7 (78)	3	2	3	3	3	3	3	1	21 (88)	3	3	3	9 (100)	3	3	2	1	9 (75)	3	3	6 (100)	High
Arg. CPG 2020 [6]	3	3	3	9 (100)	3	1	3	7 (78)	3	3	3	1	1	3	3	1	18 (75)	3	3	3	9 (100)	1	3	1	1	6 (50)	3	3	6 (100)	High
KLCA-NCC 2022 [7]	3	3	3	9 (100)	3	1	3	7 (78)	3	3	3	3	3	3	3	1	22 (92)	3	3	3	9 (100)	3	3	1	3	10 (83)	3	3	6 (100)	High
Japan CPG 2022 [8]	3	3	3	9 (100)	3	1	2	6 (67)	3	1	1	1	1	3	3	1	14 (58)	3	3	3	9 (100)	1	3	3	1	8 (67)	3	3	6 (100)	Moderate
Philippine CPG 2021 [9]	3	3	3	9 (100)	3	3	3	9 (100)	3	3	3	3	3	3	3	2	23 (96)	3	3	3	9 (100)	3	3	3	1	10 (83)	3	3	6 (100)	High
DGVS 2019 [10]	3	3	3	9 (100)	3	1	3	7 (78)	3	1	3	3	1	3	3	1	18 (75)	3	3	3	9 (100)	3	1	1	1	6 (50)	3	3	6 (100)	High
EAU/ASCO 2023 [11]	3	3	3	9 (100)	3	1	3	7 (78)	3	1	3	2	1	3	3	1	17 (71)	3	3	3	9 (100)	1	2	1	1	5 (42)	3	3	6 (100)	Moderate
ASCO 2021 [12]	3	3	3	9 (100)	3	3	3	9 (100)	3	3	3	3	3	3	3	1	22 (92)	3	3	3	9 (100)	3	3	3	3	12 (100)	3	3	6 (100)	High
ESGO/ISUOG/IOTA/ESGE 2021 [13]	3	1	3	7 (78)	3	3	3	9 (100)	3	3	3	3	1	3	3	1	20 (83)	3	3	3	9 (100)	1	3	1	1	6 (50)	3	3	6 (100)	High
SIEOG 2022 [14]	3	3	3	9 (100)	3	3	3	9 (100)	3	1	3	3	3	1	3	1	18 (75)	3	1	3	7 (78)	1	1	3	1	6 (50)	3	3	6 (100)	Moderate
Joint French CPG 2019 [15]	3	3	3	9 (100)	3	3	3	9 (100)	3	3	3	3	1	3	3	1	20 (83)	3	3	2	8 (89)	1	3	1	1	6 (50)	3	3	6 (100)	High
DGGG/DKG/DKH 2023 [16]	3	3	3	9 (100)	3	1	3	7 (78)	3	3	3	3	1	1	3	1	18 (75)	3	3	3	9 (100)	1	3	1	1	6 (50)	3	3	6 (100)	High
ESTRO/ESGO/SIOPe 2023 [17]	3	3	3	9 (100)	3	1	3	7 (78)	3	3	3	3	1	3	3	1	20 (83)	3	3	3	9 (100)	1	1	2	1	5 (42)	3	3	6 (100)	Moderate

Appendix 3. AGREE-II assessments

Guideline	Domain 1				Domain 2				Domain 3										Domain 4				Domain 5					Domain 6			Overall quality
	1	2	3	Score (%)	4	5	6	Score (%)	7	8	9	10	11	12	13	14	Score (%)	15	16	17	Score (%)	18	19	20	21	Score (%)	22	23	Score (%)		
BGCS 2022 [18]	3	1	3	7 (78)	3	1	3	7 (78)	3	1	3	2	1	3	3	1	17 (71)	3	3	3	9 (100)	1	2	1	1	5 (42)	3	3	6 (100)	Moderate	
BSH 2024 [19]	3	2	3	8 (89)	3	1	2	6 (67)	3	3	3	3	1	3	3	1	20 (83)	3	3	3	9 (100)	1	3	1	1	6 (50)	3	3	6 (100)	High	
German GdIn 2021 [20]	3	2	3	8 (89)	3	3	3	9 (100)	3	1	3	3	1	3	3	1	18 (75)	3	3	2	8 (89)	1	3	3	1	8 (67)	3	3	6 (100)	Moderate	

Abbreviations: AASLD: American Association for the Study of Liver Diseases; ACR: American College of Radiology; AIOM: Italian Association of Medical Oncology; ASCO: American Society of Clinical Oncology; BGCS: British Gynaecological Cancer Society; BSH: British Society for Haematology; CPG: Clinical Practice Guideline; DGG/DKG/DKH: German Society for Gynecology and Obstetrics, the Gynecology Oncology Working Group of the German Cancer Society and the German Cancer Aid; DGVS: German Society for Digestive and Metabolic Disorders; EAU/ASCO: European Association of Urology-American Society of Clinical Oncology; ESGO/ISUOG/ IOTA/ESGE: European Society of Gynaecological Oncology, the International Society of Ultrasound in Obstetrics and Gynecology, the International Ovarian Tumour Analysis group and the European Society for Gynaecological Endoscopy; ESTRO/ESGO/SIOPe: European Society of Gynaecological Oncology jointly with the European Society for Radiotherapy & Oncology and the European Society of Pediatric Oncology JPS: Japan Pancreas Society; NNC: National Cancer Center; SIEOG: Italian Society of Ultrasound in Obstetrics and Gynecology

Appendix 4. Evidence Tables

Table CA12. Suspected pancreatic cancer

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography; MRI: magnetic resonance imaging; MRCP: magnetic resonance cholangiopancreatography; PET: positron emission tomography; US: ultrasound	
CAR 2012 [21] Specific to adenocarcinoma of the pancreas	K29. PANCREAS: SUSPECTED DIAGNOSIS - US: Indicated [B]: Clinical presentation suggesting cancer of the pancreas should lead without delay to ultrasound of the liver, bile duct, and pancreas. Ultrasound should be performed initially if patient presents with symptoms only without abnormal lab or physical exam findings. - CT: Indicated [B]: Abdominal scan with intravenous contrast utilizing Pancreatic biphasic protocol (Arterial and Portal venous phases) can be performed when symptoms are accompanied by abnormal lab or physical examination, or if an abnormality is noted on ultrasound. Pelvic CT scan can be performed in addition to Abdominal CT scan for more accurate staging if initial ultrasound is abnormal. - MRI/MRCP: Specialized investigation [B]: MRI with contrast can be performed to further clarify clinical questions remaining from CT and ultrasound. If contrast enhanced CT scan is contraindicated (ie severe allergic reaction), MRI with contrast can be performed when symptoms are accompanied by abnormal lab or physical examination, or if an abnormality is noted on ultrasound. - ERCP/ERCP: Specialized investigation [C]: MRCP can be performed for clarification of problems. ERCP may also be needed. - PET/CT: Specialized investigation [B]: PET is not recommended for primary diagnosis of pancreatic cancer. It may have a role in depicting malignant or invasive changes in mucinous cystic neoplasms and intraductal papillary neoplasms (IPMNs). - Biopsy: Specialized investigation [B]: endoscopic procedures. If images are highly suggestive; tissue diagnosis is not needed. Tissue diagnosis can be attempted if imaging appearances are not characteristic or overlapping with other entities. It should be obtained in patients selected for palliative treatment. Biopsy can be performed using CT, ultrasound or endoscopic ultrasound.
Italian Association of Medical Oncology (AIOM) 2020 [1] (Silvertris et al)	PANCREATIC CANCER - CT (Strength: Weakly positive; QoE: Low)
Japan Pancreas Society 2023 [2] (Okusaka et al)	PANCREATIC CANCER - US (Recommendation strength: weak; evidence level: C) - Contrast-enhanced CT (Recommendation strength: strong; evidence level: B) - Abdominal MRI (Recommendation strength: weak; evidence level: C) - Endoscopic US (Recommendation strength: weak; evidence level: C) - Endoscopic retrograde cholangiopancreatography (Recommendation strength: weak; evidence level: C) - PET (Recommendation strength: weak; evidence level: C)

Appendix 4. Evidence tables

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography; MRI: magnetic resonance imaging; MRCP: magnetic resonance cholangiopancreatography; PET: positron emission tomography; US: ultrasound	
Korean NCC 2021 [3]	PANCREATIC CANCER - CT (Strength of recommendation: Strong; Level of evidence: Low). - Pancreatobiliary MRI with MRCP (Strength of recommendation: Conditional; Level of evidence: Low). - Pancreas MRI (Strength of recommendation: Conditional; Level of evidence: Moderate). - MRI (Strength of recommendation: Strong; Level of evidence: Moderate).

Abbreviations: CAR: Canadian Association of Radiologists; NCC: National Cancer Center

Table CA13. Suspected liver cancer

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
CT: computed tomography; MRI: magnetic resonance imaging; NM: nuclear medicine; PET: positron emission tomography; US: ultrasound	
CAR 2012 [21]	K26. LIVER – PRIMARY LESION HCC: DIAGNOSIS AND STAGING - US: Indicated [B]: Sensitivity for detecting small nodules is low. Screening for HCC should use ultrasound alone. Patient at risk should undergo screening at 6 month intervals. If ultrasound detects lesions less than 1 cm continued follow up with ultrasound at 3 months intervals should be performed. If follow up ultrasound shows interval increase in size then the lesion should be evaluated with Triphasic CT scan or Contrast enhanced MRI based on availability. - CT triphasic: Indicated [C]: Triphasic CT increases number of nodules detected. Sensitivity to detect HCC in cirrhotic livers is low. Arterial Hyper vascularity” and” Venous or delayed phase washout should establish the diagnosis of HCC in a cirrhotic liver. If CT scan cannot fully characterize the lesion then MRI should be performed. - MRI enhanced: Specialized investigation [B]: Better sensitivity and specificity than CT particularly in nodular cirrhotic livers. Arterial hyper vascularity” and” Venous or delayed phase washout should establish the diagnosis. - Biopsy: Indicated [C]: Diagnosis of HCC should be based on imaging characteristics of HCC on MR or CT. Biopsy can be performed if accurate diagnosis of HCC cannot be achieved by these two modalities. - NM: Specialized investigation [B]: Sulfur colloid and Gallium scan for Hepatoma assessment superior to FDG PET-CT. K28. LIVER – SECONDARY LESION: DIAGNOSIS - US: Indicated [B]: US for larger > 2 cm lesions and for guiding percutaneous biopsy. - CT: Indicated [B]: Triple phase protocol. Can identify other distal disease. - MRI: Indicated [B]: MRI if US negative but high clinical suspicion. Appropriate IV contrast required. - PET/CT: Indicated [C]: May be useful if other tests are equivocal, assuming primary tumour is FDG-avid.
American Association for the Study of Liver Diseases 2023 [4] (Singal et al)	HEPATOCELLULAR CARCINOMA - multiphasic contrast-enhanced CT, MRI (Level 3, Strong Recommendation). - dynamic contrast enhanced MRI, multiphasic CT (Level 1, Strong Recommendation). - repeat short-interval US (Level 3, Strong Recommendation). - multiphasic contrast enhanced CT, MRI (Level 1, Strong Recommendation).
ACR 2021 [5] (Chernyak et al)	LIVER LESION – INITIAL CHARACTERIZATION - Variant 1. Indeterminate, greater than 1 cm liver lesion on initial imaging with US. Normal liver. No suspicion or evidence of extrahepatic malignancy or underlying liver disease. - Variant 2. Indeterminate, greater than 1 cm liver lesion on initial imaging with CT (noncontrast or single-phase) or noncontrast MRI. Normal liver. No suspicion or evidence of extrahepatic malignancy or underlying liver disease.
Argentinian CPG 2020 [6] (Pinero et al)	HEPATOCELLULAR CARCINOMA - CT, MRI (Grade of recommendation: Strong; Quality of Evidence: High) - PET CT (Grade of recommendation: Strong; Quality of Evidence: Low to moderate)
Korean Liver Cancer	HEPATOCELLULAR CARCINOMA

Appendix 4. Evidence tables

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
CT: computed tomography; MRI: magnetic resonance imaging; NM: nuclear medicine; PET: positron emission tomography; US: ultrasound	
Association- National Cancer Centre 2022 [7]	- non invasive imaging in high-risk groups (chronic hepatitis B [A1], chronic hepatitis C [B1], or cirrhosis [A1]). - First-line: multiphasic CT, or multiphasic MRI (A1). - Second-line: multiphasic CT, multiphasic MRI (B1).
Liver Cancer Study Group of Japan 2022 [8] (Kubo et al)	INTRAHEPATIC CHOLANGIOCARCINOMA - Abdominal US, CT, and MRI (Strong recommendation).
Philippine Guideline 2021 [9] (Barroso et al)	HEPATOCELLULAR CARCINOMA - multiphasic, contrast-enhanced CT scan, contrast-enhanced MRI (Strength: Strong; Certainty of evidence: Low).

Abbreviations: CAR: Canadian Association of Radiologists

Table CA14. Incidental liver mass

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
	CT: computed tomography; MRI: magnetic resonance imaging; US: ultrasound
CAR 2012 [21]	This scenario was not addressed in 2012.
ACR 2021 [5]	LIVER LESION – INITIAL CHARACTERIZATION - Variant 5. Incidental liver lesion, greater than 1 cm on US, noncontrast or single-phase CT, or noncontrast MRI. Known chronic liver disease. - Variant 8. Incidental liver lesion, less than 1 cm on US, noncontrast or single-phase CT, or noncontrast MRI. Known chronic liver disease.

Abbreviations: ACR: American College of Radiology; CAR: Canadian Association of Radiologists

Table CA16. Suspected anal cancer

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
CT: computed tomography; FDG: Fludeoxyglucose F ¹⁸ ; IV: intravenous; MRI: magnetic resonance imaging; PET: positron emission tomography	
CAR 2012 [21]	K31. COLORECTAL CANCER: DIAGNOSIS - Optical Colonoscopy: Indicated [A]: Examination of choice. - CT Colonography: Indicated [A]: Indicated when colonoscopy incomplete, contra-indicated or unavailable. - Double contrast barium enema: Specialized investigation [B]: Due to inferior sensitivity cannot be considered an alternative to colonoscopy. May be considered only when colonoscopy or CT colonography is not available. - CT abdomen and pelvis with IV iodinated contrast: Specialized investigation [C]: Inferior to CT Colonography may be considered second line for advanced neoplasia in elderly or infirmed patient unable to tolerate bowel prep and insufflations. - MRI abdomen with IV gadolinium contrast: Specialized investigation [C]: Small studies suggest high sensitivity and specificity. But experience is limited in North America. Should only be performed by those with experience. - FDG/PET/CT: Not indicated [C]: There is no evidence for use of PET for routine diagnosis of colorectal cancer. Although PET may detect CRC incidentally, it is not indicated due to high false positive and false negative rate and availability of more appropriate tests such as colonoscopy or CT colonography.
German Guidelines 2019 [10] (Vogl et al)	COLORECTAL CANCER - CT - MR colonography

Abbreviations: CAR: Canadian Association of Radiologists

Table CA21. Suspected penile cancer

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
MRI: magnetic resonance imaging; US: ultrasound	
CAR 2012 [21]	Not covered in the 2012 guideline.
EAU/ASCO 2023 [11] (Brouwer et al)	PENILE CANCER (PRIMARY TUMOUR) - MRI - US

Abbreviations: CAR: Canadian Association of Radiologists; EAU/ASCO: European Association of Urology and the American Society of Clinical Oncology

Table CA23. Suspected ovarian cancer

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; US: ultrasound	
CAR 2012 [21]	K51. GYNCOLOGICAL CANCERS – OVARY: DIAGNOSIS - US: Indicated [A]: Ovarian masses are frequently detected on sonography. Transabdominal as well as transvaginal views are mandatory. US can be limited by limited field of view and bowel gas. - MRI abdomen/pelvis: Indicated [B]: MRI is the most sensitive and specific problem-solving modality for characterizing adnexal masses.
American Society of Clinical Oncology 2021 [12] (Vanderpuye et al)	OVARIAN CANCER - US (abdominal and transvaginal US, Doppler-enhanced) - contrast-enhanced CT of abdomen and pelvis ($\pm$ thorax)
ESGO/ISUOG/ IOTA/ESGE 2021 [13] (Timmerman et al)	OVARIAN TUMOURS - US - MRI - PET-CT - whole-body diffusion MRI - PET-CT
SIEOG 2022 [14]	ADNEXAL MASS - Transvaginal US - Transabdominal US
Joint French CPG 2019 [15] (Lavoue et al)	OVARIAN MASS - Transvaginal and transabdominal US - pelvic MRI

Abbreviations: ASCO: American Society of Clinical Oncology; CAR: Canadian Association of Radiologists; CPG : Clinical Practice Guideline; ESGO/ISUOG/ IOTA/ESGE: European Society of Gynaecological Oncology, the International Society of Ultrasound in Obstetrics and Gynecology, the International Ovarian Tumour Analysis group and the European Society for Gynaecological Endoscopy; SIEOG: Italian Society For Ultrasound In Obstetrics And Gynecology

Table CA24. Suspected cervical cancer

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
	CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; US: ultrasound
CAR 2012 [21]	K51. GYNECOLOGICAL CANCERS – UTERUS: CERVIX: DIAGNOSIS - MRI pelvis only: Indicated [A]: MRI is the most sensitive and specific imaging modality for LOCAL staging of cervical cancer when compared to CT. CT is best for detection of distant nodes and visceral disease. Usually, both are performed. Some centres now use transrectal US for local invasion, depending on availability of expertise. - CT abdomen/pelvis: Indicated [A]: MRI is the most sensitive and specific imaging modality for LOCAL staging of cervical cancer when compared to CT. CT is best for detection of distant nodes and visceral disease. Usually, both are performed. Some centres now use transrectal US for local invasion, depending on availability of expertise. - PET-CT: Indicated only in specific circumstances [B]: PET is useful in difficult situations to define the extent of disease with accompanying image registration. Not indicated for early cancers. Level C evidence for advanced cancers. Also useful in assessment of nodal metastases although its impact in this respect on clinical outcome is still being evaluated.

Abbreviations: CAR: Canadian Association of Radiologists

Table CA25. Suspected endometrial/uterine cancer

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
MRI: magnetic resonance imaging; US: ultrasound	
CAR 2012 [21]	K57. GYNECOLOGICAL CANCERS – UTERUS: BODY: DIAGNOSIS - US/MRI: Indicated [B]: US is used for detection and triaging for endometrial biopsy. Staging is surgicopathological. MRI is reserved for problem solving and differentiating benign from malignant lesions.
British Gynaecological Cancer Society 2022 [18] (Morrison et al)	UTERINE CANCER - Transvaginal US
German Guideline 2023 [16] (Emons et al)	ENDOMETRIAL CANCER - Transvaginal US - MRI
Italian Society For Ultrasound In Obstetrics And Gynecology (SIEOG) 2022 [14]	- Transvaginal US - pelvic US

Abbreviations: CAR: Canadian Association of Radiologists

Table CA26. Suspected vulvar cancer

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
CAR 2012 [21]	K59. VULVAR CANCER: DIAGNOSIS - Vulvar cancer lesions can be detected visibly or by palpation. Biopsy of suspicious lesions should be performed immediately.

Abbreviations: CAR: Canadian Association of Radiologists

Table CA27. Suspected vaginal cancer

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
	CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; US: ultrasound
CAR 2012 [21]	K62. VAGINAL CANCER: DIAGNOSIS - Diagnosis based on clinical symptoms and findings. PAP (Papanicolaou) smear, targeted biopsy or colposcopy to confirm diagnosis.
ESTRO/ESGO/SIOPe 2023 [17] (Nout et al)	VAGINAL CANCER - MRI - pelvic US - CT chest-abdomen-pelvis - PET-CT

Abbreviations: CAR: Canadian Association of Radiologists; ESTRO/ESGO/SIOPe: European Society for Radiotherapy & Oncology, European Society of Gynaecological Oncology, European Society of Pediatric Oncology

Table CA28. Suspected hematologic malignancies

Guideline Group	Imaging modality addressed in guideline recommendations and/or clinical scenarios covered
CT: computed tomography; MRI: magnetic resonance imaging; NM: nuclear medicine; PET: positron emission tomography; US: ultrasound	
CAR 2012 [21]	K65. LYMPHOMA: DIAGNOSIS - CT: Indicated [B]: For evaluation of extent of clinically suspected adenopathy and selection of site for biopsy. - NM: Specialized investigation [B]: Being replaced by PET.
British Society for Haematology 2024 [19] (Hughes et al)	SMOULDERING MYELOMA - Cross-sectional imaging (i.e. diffusion-weighted whole-body MRI, PET-CT) - Skeletal survey
German CPG 2021 [20] (Zoellner et al)	FOLLICULAR LYMPHOMA - CT neck, thorax, abdomen - US

Abbreviations: CAR: Canadian Association of Radiologists; CPG: Clinical practice guideline

References

- [1] Silvestris N, Brunetti O, Bittoni A, Cataldo I, Corsi D, Crippa S, et al. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). *Cancers* 2020;12:1681. <https://doi.org/10.3390/cancers12061681>.
- [2] Okusaka T, Nakamura M, Yoshida M, Kitano M, Ito Y, Mizuno N, et al. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. *Int J Clin Oncol* 2023;28:493–511. <https://doi.org/10.1007/s10147-023-02317-x>.
- [3] Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, Korea. Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. *Pancreatol Off J Int Assoc Pancreatol IAP AI* 2021;21:1326–41. <https://doi.org/10.1016/j.pan.2021.05.004>.
- [4] Singal AG, Llovet JM, Yarrow M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatol Baltim Md* 2023;78:1922–65. <https://doi.org/10.1097/HEP.0000000000000466>.
- [5] Expert Panel on Gastrointestinal Imaging, Chernyak V, Horowitz JM, Kamel IR, Arif-Tiwari H, Bashir MR, et al. ACR Appropriateness Criteria® Liver Lesion-Initial Characterization. *J Am Coll Radiol JACR* 2020;17:S429–46. <https://doi.org/10.1016/j.jacr.2020.09.005>.
- [6] Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, et al. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. *Ann Hepatol* 2020;19:546–69. <https://doi.org/10.1016/j.aohep.2020.06.003>.
- [7] Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. *Clin Mol Hepatol* 2022;28:583–705. <https://doi.org/10.3350/cmh.2022.0294>.
- [8] Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, Izumi N, et al. Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. *Liver Cancer* 2022;11:290–314. <https://doi.org/10.1159/000522403>.
- [9] Barroso R, David A, Abisinia I, Orillaza T, Semilla-Lim B, Nolasco J, et al. The Philippine Clinical Practice Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma 2021. *Philipp J Intern Med* 2021;59:166–95.
- [10] Vogl TJ, Pereira PL, Helmberger T, Schreyer AG, Schmiegeler W, Fischer S, et al. Updated S3 Guidelines - Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention. *ROFO Fortschr Geb Rontgenstr Nuklearmed* 2019;191:298–310. <https://doi.org/10.1055/a-0721-1947>.
- [11] Brouwer OR, Albersen M, Parnham A, Protzel C, Pettaway CA, Ayres B, et al. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. *Eur Urol* 2023;83:548–60. <https://doi.org/10.1016/j.eururo.2023.02.027>.
- [12] Vanderpuye VD, Clemenceau JRV, Temin S, Aziz Z, Burke WM, Cevallos NL, et al. Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline. *JCO Glob Oncol* 2021;7:1032–66. <https://doi.org/10.1200/GO.21.00085>.
- [13] Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, et al. ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours. *Facts Views Vis ObGyn* 2021;13:107–30. <https://doi.org/10.52054/FVVO.13.2.016>.
- [14] The Italian Society For Ultrasound In Obstetrics And Gynecology Sieog null. The Italian guidelines on ultrasound in obstetrics and gynecology: Executive summary of recommendations for practice. *Eur J Obstet Gynecol Reprod Biol* 2022;279:176–82. <https://doi.org/10.1016/j.ejogrb.2022.10.016>.

- [15] Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, et al. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology. *J Gynecol Obstet Hum Reprod* 2019;48:369–78. <https://doi.org/10.1016/j.jogoh.2019.03.017>.
- [16] Emons G, Steiner E, Vordermark D, Uleer C, Paradies K, Tempfer C, et al. Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures. *Geburtshilfe Frauenheilkd* 2023;83:919–62. <https://doi.org/10.1055/a-2066-2051>.
- [17] Nout RA, Calaminus G, Planchamp F, Chargari C, Lax S, Martelli H, et al. ESTRO/ESGO/SIOPe Guidelines for the management of patients with vaginal cancer. *Int J Gynecol Cancer Off J Int Gynecol Cancer Soc* 2023;33:1185–202. <https://doi.org/10.1136/ijgc-2023-004695>.
- [18] Morrison J, Balega J, Buckley L, Clamp A, Crosbie E, Drew Y, et al. British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice. *Eur J Obstet Gynecol Reprod Biol* 2022;270:50–89. <https://doi.org/10.1016/j.ejogrb.2021.11.423>.
- [19] Hughes D, Yong K, Ramasamy K, Stern S, Boyle E, Ashcroft J, et al. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper. *Br J Haematol* 2024;204:1193–206. <https://doi.org/10.1111/bjh.19333>.
- [20] Zoellner A, Herfarth K, Herold M, Klapper W, Skoetz N, Hiddemann W, et al. Clinical Practice Guideline: Follicular Lymphoma—Diagnosis, Treatment, and Follow-up. *Dtsch Arzteblatt Int* 2021;118:320–5. <https://doi.org/10.3238/arztebl.m2021.0022>.
- [21] Canadian Association of Radiologists. 2012 CAR Diagnostic Imaging Referral Guidelines. Canadian Association of Radiologists; 2012.